Thera-SAbDab

PEPINEMAB

>   Structural Summary
TherapeuticPepinemab
TargetSEMA4D
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS
Light ChainDIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedBristol-Myers Squibb, Children's Oncology Group, Emory University, Merck KGaA, National Cancer Institute (USA), Teva Pharmaceutical Industries, UCLAs Jonsson Comprehensive Cancer Center, Vaccinex
Conditions Approvedna
Conditions ActiveHuntington's disease, Non-small cell lung cancer, Osteosarcoma, Solid tumours, Colorectal cancer, Head and neck cancer, Malignant melanoma, Pancreatic cancer
Conditions DiscontinuedMultiple sclerosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]